【佳學(xué)基因檢測(cè)】實(shí)體瘤個(gè)體化醫(yī)療的新策略：分子標(biāo)志物和臨床試驗(yàn)設(shè)計(jì)

腫瘤基因檢測(cè)需要多長時(shí)間香港

根據(jù)如何選擇有效的靶向藥物治療認(rèn)識(shí)到《Clin Cancer Res》在.?2014 Sep 1;20(17):4425-35.發(fā)表了一篇題目為《實(shí)體瘤個(gè)體化醫(yī)療的新策略：分子標(biāo)志物和臨床試驗(yàn)設(shè)計(jì)》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Juliane M Jürgensmeier?,?Joseph P Eder?,?Roy S Herbst?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤標(biāo)志物研究?jī)?nèi)容關(guān)鍵詞：

實(shí)體瘤,個(gè)體化醫(yī)療,新策略,伴隨檢測(cè),基因檢測(cè)

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

了解腫瘤生物學(xué)的信號(hào)通路的描述，加上允許廣泛分子譜分析和數(shù)據(jù)分析的技術(shù)的快速發(fā)展，導(dǎo)致了腫瘤學(xué)個(gè)性化醫(yī)療的新時(shí)代?，F(xiàn)在，許多學(xué)術(shù)機(jī)構(gòu)在提出治療建議之前，定期在個(gè)性化醫(yī)學(xué)腫瘤委員會(huì)會(huì)議上對(duì)患者進(jìn)行分析并討論他們的病例。制藥公司發(fā)起的臨床試驗(yàn)通常需要特定的基因檢測(cè)標(biāo)志物才能注冊(cè)，或者至少為未來的標(biāo)志物探索多種選擇。除了少數(shù)被批準(zhǔn)用于治療組織學(xué)和分子明確的腫瘤患者的靶向藥物外，大量正在開發(fā)的新型靶向藥物正在進(jìn)行臨床研究，并通過基因檢測(cè)進(jìn)行伴隨分析以確定反應(yīng)賊佳的患者群體。盡管目前分析的重點(diǎn)在于遺傳分析，但正在開發(fā)額外的 RNA、蛋白質(zhì)和免疫參數(shù)測(cè)試并將其納入臨床研究，這些方法可能會(huì)對(duì)未來的患者選擇和治療方法做出重大貢獻(xiàn)。隨著腫瘤生物學(xué)和人類遺傳學(xué)的進(jìn)步已經(jīng)確定了有希望的腫瘤靶點(diǎn)，正在進(jìn)行的新藥臨床評(píng)估現(xiàn)在需要證明這一承諾是否可以轉(zhuǎn)化為對(duì)患者的益處。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

The delineation of signaling pathways to understand tumor biology combined with the rapid development of technologies that allow broad molecular profiling and data analysis has led to a new era of personalized medicine in oncology. Many academic institutions now routinely profile patients and discuss their cases in meetings of personalized medicine tumor boards before making treatment recommendations. Clinical trials initiated by pharmaceutical companies often require specific markers for enrollment or at least explore multiple options for future markers. In addition to the still small number of targeted agents that are approved for the therapy of patients with histological and molecularly defined tumors, a broad range of novel targeted agents in development are undergoing clinical studies with companion profiling to determine the best-responding patient population. Although the present focus of profiling lies in genetic analyses, additional tests of RNA, protein, and immune parameters are being developed and incorporated in clinical research, and these methods are likely to contribute significantly to future patient selection and treatment approaches. As the advances in tumor biology and human genetics have identified promising tumor targets, the ongoing clinical evaluation of novel agents will now need to show if the promise can be translated into benefit for patients.